White oil is positioned as a high-purity segment of specialty hydrocarbons. IndexBox describes it as colorless, odorless, and inert, achieved through intensive hydrotreatment, which makes it suitable where purity and stability are non-negotiable. The same source links forward demand to pharmaceuticals, personal care, and food processing, while noting market complexity from tightening standards, clean-label preferences, and supply chain shifts tied to feedstock availability and geopolitics. For GCC players evaluating a premium lane, pharmaceutical white oil GCC strategies tend to hinge on meeting pharmacopoeia expectations and supplying customers that require controlled quality and consistent documentation.
Several forecasts underline that white oils are growing, but the pace and assumptions vary by source. Mordor Intelligence projects global volume rising from 1.56 million tons in 2025 to 1.58 million tons in 2026 and reaching 1.69 million tons by 2031, at a 1.36% CAGR for 2026–2031. By contrast, Global Market Insights states the market size exceeded USD 2.9 billion in 2025 and expects 4.5% CAGR from 2026 to 2035. Another global estimate from GIIR values the market at USD 2.25 billion in 2024 and expects USD 2.88 billion by 2030 at 4.18% CAGR. These are global figures, but they frame why premium grades matter.
Why High-Purity Grades Make the Segment “Specialty”
Market structure is increasingly skewed toward pharmaceutical-grade material. Mordor Intelligence reports pharmaceutical grade held 66.23% of global share in 2025 and is advancing at a 1.32% CAGR to 2031. The same report says Group II base oils accounted for 67.12% share in 2025 (1.73% CAGR to 2031), and low-viscosity grades were 51.08% of 2025 volume (1.41% CAGR to 2031). It also ties demand shifts to compliance: hydrocracked Group II and III oils comply with U.S. and European pharmacopoeial limits on sulfur, nitrogen, and polycyclic aromatic hydrocarbons, which pushes buyers toward high-purity supply chains rather than commodity streams.
End-use signals also support a specialty positioning. Mordor Intelligence attributes 25.56% of 2025 white oil demand to personal care, advancing at a 2.11% CAGR to 2031, and notes personal-care brands in India and the Middle East rely on light-paraffinic carriers aligned with Ayurvedic and halal standards. Custom Market Insights lists cosmetics and beauty applications such as detergent creams, cold creams, bronzed oils, hydrating creams, and makeup, and pharmaceutical uses including internal lubricants, emollients, ointments, and laxatives. IndexBox further emphasizes pharmaceutical use as lubricants, excipients, and processing aids in tablet manufacturing and ointments, reinforcing the value of consistent purity and batch documentation.
For GCC manufacturers, the strategic question is how to compete against established approval systems while leveraging the region’s feedstock advantages. A QYResearch press release notes that North America and Europe maintain higher shares of certified pharmaceutical, food, and cosmetic grades, influenced by strict documentation and regulated downstream industries. The same source states the Middle East benefits from access to petroleum and natural-gas feedstocks and is developing additional specialty-oil manufacturing capacity. Globally, IndexBox projects a baseline CAGR of approximately 3.2% from 2026 to 2035, with a market index reaching 135 by 2035 relative to a 2025 baseline of 100, suggesting durable demand for suppliers that can deliver the required purity, stability, and documentation package.
What is white oil, and why is it used in pharmaceuticals and cosmetics?
How large is the pharmaceutical-grade share of the global white oil market?
Which grades and characteristics are gaining emphasis in global procurement?
What does global market growth look like for white oils across forecasts?
What does a pharmaceutical white oil GCC strategy need to prioritize to win premium accounts?
